Do Topical Antibiotics Improve Skin Graft Results?

NCT ID: NCT07286851

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

142 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-01

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to see if putting antibiotic ointment on a skin graft when the surgery is being done helps prevent the skin graft from getting infected after the operation. The study is looking at all skin grafts done in a rural Bangladesh hospital.

The main questions it aims to answer are:

Does the antibiotic lower the number of infections that happen? Does the antibiotic make the overall outcome of the skin graft better? Do patients who get the antibiotic need fewer extra surgeries?

Researchers will compare the outcomes from patients who had skin grafts before the hospital started applying antibiotic ointment to the outcomes of patients after the hospital began applying antibiotic ointment.

Participants who have already had their skin graft treatment completed will have their medical records reviewed by researchers. The outcomes of their treatment will be written down.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Transplantation Wounds and Injuries Antibiotic Prophylaxis Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Patients who had skin graft procedure before the topical antibiotic protocol was initiated

No interventions assigned to this group

Neomycin

Patients who had skin graft procedure after the topical antibiotic protocol was initiated. Patients had topical neomycin applied at the time of their surgeries.

Neomycin

Intervention Type DRUG

Topical neomycin was applied at the time of split-thickness skin graft surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neomycin

Topical neomycin was applied at the time of split-thickness skin graft surgery.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient undergoing a split-thickness skin graft at the hospital where research is conducted

Exclusion Criteria

* Missing or incomplete medical record
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LAMB Project

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonathan Egle

General Surgeon, Deputy Medical Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

LAMB Hospital

Parbatipur, Dinajpur, Bangladesh

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bangladesh

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REC2025/03

Identifier Type: -

Identifier Source: org_study_id